{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T04:40:15Z","timestamp":1784263215965,"version":"3.55.0"},"reference-count":47,"publisher":"Society of Nuclear Medicine","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Nucl. Med.\n                Technol."],"accepted":{"date-parts":[[2026,3,12]]},"published-print":{"date-parts":[[2026,6]]},"DOI":"10.2967\/jnmt.125.271978","type":"journal-article","created":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T16:25:13Z","timestamp":1776097513000},"page":"127-135","source":"Crossref","is-referenced-by-count":4,"title":["Prostate Cancer, Part 1: Contemporary Radioligands"],"prefix":"10.2967","volume":"54","author":[{"given":"Geoffrey M.","family":"Currie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric M.","family":"Rohren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1602","published-online":{"date-parts":[[2026,4,13]]},"reference":[{"key":"2026060306101369000_54.2.127.1","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.semradonc.2025.04.003","article-title":"Radiopharmaceuticals in prostate cancer: general considerations and utility in combination with EBRT","volume":"35","author":"Civan","year":"2025","journal-title":"Semin Radiat Oncol."},{"key":"2026060306101369000_54.2.127.2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2023.09.003"},{"key":"2026060306101369000_54.2.127.3","doi-asserted-by":"publisher","DOI":"10.2967\/jnmt.125.270169"},{"key":"2026060306101369000_54.2.127.4","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1053\/j.semnuclmed.2025.01.007","article-title":"Sharpening the blade of precision theranostics","volume":"55","author":"Currie","year":"2025","journal-title":"Semin Nucl Med."},{"key":"2026060306101369000_54.2.127.5","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1002\/jmrs.836","article-title":"Molecular theranostics: principles, challenges and controversies","volume":"72","author":"Currie","year":"2025","journal-title":"J Med Radiat Sci."},{"key":"2026060306101369000_54.2.127.6","doi-asserted-by":"publisher","DOI":"10.2967\/jnmt.125.271979"},{"key":"2026060306101369000_54.2.127.7","doi-asserted-by":"publisher","DOI":"10.7150\/thno.40599"},{"key":"2026060306101369000_54.2.127.8","doi-asserted-by":"crossref","first-page":"16","DOI":"10.3390\/ph12010016","article-title":"Can the efficacy of [18F]FDG-PET\/CT in clinical oncology be enhanced by screening biomolecular profiles?","volume":"12","author":"O\u2019Neill","year":"2019","journal-title":"Pharmaceuticals (Basel)."},{"key":"2026060306101369000_54.2.127.9","first-page":"367","article-title":"PET\/CT in prostate cancer: non-choline radiopharmaceuticals","volume":"56","author":"Castellucci","year":"2012","journal-title":"Q J Nucl Med Mol Imaging."},{"key":"2026060306101369000_54.2.127.10","doi-asserted-by":"publisher","DOI":"10.3892\/or.2013.2886"},{"key":"2026060306101369000_54.2.127.11","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.115.170704"},{"key":"2026060306101369000_54.2.127.12","doi-asserted-by":"publisher","DOI":"10.1126\/science.1160809"},{"key":"2026060306101369000_54.2.127.13","doi-asserted-by":"crossref","first-page":"7954854","DOI":"10.1155\/2019\/7954854","article-title":"Nuclear imaging of glucose metabolism: beyond 18F-FDG","volume":"2019","author":"Feng","year":"2019","journal-title":"Contrast Media Mol Imaging."},{"key":"2026060306101369000_54.2.127.14","doi-asserted-by":"crossref","first-page":"94969","DOI":"10.18632\/oncotarget.21662","article-title":"18F-fluoromisonidazole in tumor hypoxia imaging","volume":"8","author":"Xu","year":"2017","journal-title":"Oncotarget."},{"key":"2026060306101369000_54.2.127.15","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-011-1876-z"},{"key":"2026060306101369000_54.2.127.16","doi-asserted-by":"crossref","first-page":"10005","DOI":"10.18632\/oncotarget.24234","article-title":"Evaluation of tumor hypoxia prior to radiotherapy in intermediate-risk prostate cancer using 18F-fluoromisonidazole PET\/CT: a pilot study","volume":"9","author":"Supiot","year":"2018","journal-title":"Oncotarget."},{"key":"2026060306101369000_54.2.127.17","doi-asserted-by":"crossref","first-page":"W698","DOI":"10.2214\/AJR.12.9698","article-title":"PET with 62Cu-ATSM and 62Cu-PTSM is a useful imaging tool for hypoxia and perfusion in pulmonary lesions","volume":"201","author":"Zhang","year":"2013","journal-title":"AJR."},{"key":"2026060306101369000_54.2.127.18","doi-asserted-by":"publisher","DOI":"10.1053\/j.semnuclmed.2004.06.004"},{"key":"2026060306101369000_54.2.127.19","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1007\/s11934-016-0575-5","article-title":"Prostate cancer imaging with novel PET tracers","volume":"17","author":"Lindenberg","year":"2016","journal-title":"Curr Urol Rep."},{"key":"2026060306101369000_54.2.127.20","doi-asserted-by":"crossref","first-page":"17562872221105018","DOI":"10.1177\/17562872221105018","article-title":"Role of molecular imaging in the detection of localized prostate cancer","volume":"14","author":"Galgano","year":"2022","journal-title":"Ther Adv Urol."},{"key":"2026060306101369000_54.2.127.21","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.ymeth.2017.07.009","article-title":"New aspects of molecular imaging in prostate cancer","volume":"130","author":"Ceci","year":"2017","journal-title":"Methods."},{"key":"2026060306101369000_54.2.127.22","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.3389\/fonc.2019.01438","article-title":"Diagnostic performance of PET\/CT using 18F-FACBC in prostate cancer: a meta-analysis","volume":"9","author":"Bin","year":"2020","journal-title":"Front Oncol."},{"key":"2026060306101369000_54.2.127.23","doi-asserted-by":"crossref","first-page":"304","DOI":"10.3390\/diagnostics11020304","article-title":"18F-fluciclovine positron emission tomography in prostate cancer: a systematic review and diagnostic meta-analysis","volume":"11","author":"Biscontini","year":"2021","journal-title":"Diagnostics."},{"key":"2026060306101369000_54.2.127.24","doi-asserted-by":"crossref","first-page":"e226","DOI":"10.1097\/RLU.0000000000002130","article-title":"Diagnostic performance of 18F-fluciclovine in detection of prostate cancer bone metastases","volume":"43","author":"Chau","year":"2018","journal-title":"Clin Nucl Med."},{"key":"2026060306101369000_54.2.127.25","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.juro.2018.08.050","article-title":"The impact of positron emission tomography with 18F-fluciclovine on the treatment of biochemical recurrence of prostate cancer: results from the LOCATE trial","volume":"201","author":"Andriole","year":"2019","journal-title":"J Urol."},{"key":"2026060306101369000_54.2.127.26","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djt241"},{"key":"2026060306101369000_54.2.127.27","first-page":"1367","article-title":"Investigation of transport mechanism and uptake kinetics of O-(2-[18F]fluoroethyl)-l-tyrosine in\u00a0vitro and in\u00a0vivo","volume":"40","author":"Heiss","year":"1999","journal-title":"J Nucl Med."},{"key":"2026060306101369000_54.2.127.28","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.107.046391"},{"key":"2026060306101369000_54.2.127.29","first-page":"1757","article-title":"[11C]thymidine and FDG to measure therapy response","volume":"39","author":"Shields","year":"1998","journal-title":"J Nucl Med."},{"key":"2026060306101369000_54.2.127.30","first-page":"290","article-title":"Analysis of 2-carbon-11-thymidine blood metabolites in PET imaging","volume":"37","author":"Shields","year":"1996","journal-title":"J Nucl Med."},{"key":"2026060306101369000_54.2.127.31","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-004-1687-6"},{"key":"2026060306101369000_54.2.127.32","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0058938"},{"key":"2026060306101369000_54.2.127.33","first-page":"292","article-title":"Imaging DNA synthesis in\u00a0vivo with 18F-FMAU and PET","volume":"46","author":"Sun","year":"2005","journal-title":"J Nucl Med."},{"key":"2026060306101369000_54.2.127.34","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-008-0738-9"},{"key":"2026060306101369000_54.2.127.35","doi-asserted-by":"publisher","DOI":"10.1210\/er.2002-0032"},{"key":"2026060306101369000_54.2.127.36","doi-asserted-by":"publisher","DOI":"10.1007\/s12094-009-0304-3"},{"key":"2026060306101369000_54.2.127.37","first-page":"366","article-title":"Tumor localization of 16\u03b2-18F-fluoro-5\u03b1-dihydrotestosterone versus 18F-FDG in patients with progressive, metastatic prostate cancer","volume":"45","author":"Larson","year":"2004","journal-title":"J Nucl Med."},{"key":"2026060306101369000_54.2.127.38","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-005-1764-5"},{"key":"2026060306101369000_54.2.127.39","doi-asserted-by":"crossref","first-page":"522","DOI":"10.3390\/ph18040522","article-title":"Fibroblast activation protein inhibitor (FAPI)-based theranostics","volume":"18","author":"Serumula","year":"2025","journal-title":"Pharmaceuticals (Basel)."},{"key":"2026060306101369000_54.2.127.40","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.118.210443"},{"key":"2026060306101369000_54.2.127.41","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.119.233122"},{"key":"2026060306101369000_54.2.127.42","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/s44303-024-00053-z","article-title":"Clinical applications of fibroblast activation protein inhibitor positron emission tomography (FAPI-PET)","volume":"2","author":"Mori","year":"2024","journal-title":"Npj Imaging."},{"key":"2026060306101369000_54.2.127.43","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.119.227967"},{"key":"2026060306101369000_54.2.127.44","doi-asserted-by":"publisher","DOI":"10.1038\/nrc.2016.73"},{"key":"2026060306101369000_54.2.127.45","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.115.166512"},{"key":"2026060306101369000_54.2.127.46","doi-asserted-by":"crossref","first-page":"2533","DOI":"10.3390\/biomedicines10102533","article-title":"The performance of FDA-approved PET imaging agents in the detection of prostate cancer","volume":"10","author":"Li","year":"2022","journal-title":"Biomedicines."},{"key":"2026060306101369000_54.2.127.47","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1097\/MNM.0000000000001621","article-title":"Bone metastases in prostate cancer: gallium-68-labeled prostate-specific membrane antigen or fluorine 18 sodium fluoride PET\/computed tomography\u2014the better tracer?","volume":"43","author":"Agrawal","year":"2022","journal-title":"Nucl Med Commun."}],"container-title":["Journal of Nuclear Medicine Technology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.2967\/jnmt.125.271978","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T13:10:52Z","timestamp":1780492252000},"score":1,"resource":{"primary":{"URL":"http:\/\/tech.snmjournals.org\/lookup\/doi\/10.2967\/jnmt.125.271978"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,13]]},"references-count":47,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,6,3]]},"published-print":{"date-parts":[[2026,6]]}},"alternative-id":["10.2967\/jnmt.125.271978"],"URL":"https:\/\/doi.org\/10.2967\/jnmt.125.271978","relation":{},"ISSN":["0091-4916","1535-5675"],"issn-type":[{"value":"0091-4916","type":"print"},{"value":"1535-5675","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,13]]}}}